These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 7127661

  • 1. A phase I trial of combination therapy with continuous-infusion PALA and continuous-infusion 5-FU.
    Weiss GR, Ervin TJ, Meshad MW, Schade D, Branfman AR, Bruni RJ, Chadwick M, Kufe DW.
    Cancer Chemother Pharmacol; 1982; 8(3):301-4. PubMed ID: 7127661
    [Abstract] [Full Text] [Related]

  • 2. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Grem JL, McAtee N, Steinberg SM, Hamilton JM, Murphy RF, Drake J, Chisena T, Balis F, Cysyk R, Arbuck SG.
    Cancer Res; 1993 Oct 15; 53(20):4828-36. PubMed ID: 8402669
    [Abstract] [Full Text] [Related]

  • 3. Phase I-phase II trial of N-phosphonacetyl-L-aspartic acid given by intravenous infusion and 5-fluorouracil given by bolus injection.
    Erlichman C, Donehower RC, Speyer JL, Klecker R, Chabner BA.
    J Natl Cancer Inst; 1982 Feb 15; 68(2):227-31. PubMed ID: 6950156
    [Abstract] [Full Text] [Related]

  • 4. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
    Ardalan B, Singh G, Silberman H.
    J Clin Oncol; 1988 Jun 15; 6(6):1053-8. PubMed ID: 3373260
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
    Ardalan B, Sridhar KS, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Fodor M, Livingstone A.
    Cancer; 1991 Sep 15; 68(6):1242-6. PubMed ID: 1873776
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
    O'Dwyer PJ, Hudes GR, Colofiore J, Walczak J, Hoffman J, LaCreta FP, Comis RL, Martin DS, Ozols RF.
    J Natl Cancer Inst; 1991 Sep 04; 83(17):1235-40. PubMed ID: 1714507
    [Abstract] [Full Text] [Related]

  • 13. Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
    Chiuten DF, Miller A, Valdivieso M, Loo TL, Bedikian A, Bodey GP, Benvenuto JA, Freireich EJ.
    Am J Clin Oncol; 1985 Aug 04; 8(4):332-5. PubMed ID: 4083263
    [Abstract] [Full Text] [Related]

  • 14. PALA in advanced breast cancer. A phase II pilot study by the ECOG.
    Taylor SG, Davis TE, Falkson G, Keller AM.
    Am J Clin Oncol; 1982 Dec 04; 5(6):627-9. PubMed ID: 7165004
    [Abstract] [Full Text] [Related]

  • 15. Pilot study of PALA and 5-FU in patients with advanced cancer.
    O'Connell MJ, Powis G, Rubin J, Moertel CG.
    Cancer Treat Rep; 1982 Jan 04; 66(1):77-80. PubMed ID: 7053270
    [Abstract] [Full Text] [Related]

  • 16. Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
    Presant CA, Ardalan B, Multhauf P, Chan C, Staples R, Green L, Browning S, Carr BI, Chang FF, Thayer W.
    Med Pediatr Oncol; 1983 Jan 04; 11(3):162-3. PubMed ID: 6222250
    [Abstract] [Full Text] [Related]

  • 17. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
    Royce ME, McGarry W, Bready B, Dakhil SR, Belt RJ, Goodwin JW, Gray R, Hoff PM, Winn R, Pazdur R.
    J Clin Oncol; 1999 Oct 04; 17(10):3276-82. PubMed ID: 10506630
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of N-(phosphonacetyl)-L-aspartate with fluorouracil and with or without dipyridamole in patients with advanced cancer.
    Fleming RA, Capizzi RL, Muss HB, Smith S, Fernandes DJ, Homesley H, Loggie BW, Case L, Morris R, Russell GB, Richards F.
    Clin Cancer Res; 1996 Jul 04; 2(7):1107-14. PubMed ID: 9816275
    [Abstract] [Full Text] [Related]

  • 19. N-(phosphonacetyl)-L-aspartate (PALA) in advanced soft tissue sarcoma: a phase II trial of the EORTC soft tissue sarcoma group.
    Bramwell V, Van Oosterom A, Mouridsen HT, Cheix F, Somers R, Thomas D, Rozencweig M.
    Eur J Cancer Clin Oncol; 1982 Jan 04; 18(1):81-4. PubMed ID: 6211362
    [Abstract] [Full Text] [Related]

  • 20. N-(phosphonacetyl)-L-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group.
    Paridaens R, Mouridsen HT, Palshof T, Cocconi G, Van Oosterom A, Rotmensz N, Sylvester R, Heuson JC, Rozencweig M.
    Eur J Cancer Clin Oncol; 1982 Jan 04; 18(1):67-70. PubMed ID: 6211361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.